Literature DB >> 8497712

Safety of high-dose inhaled corticosteroids.

N C Barnes1.   

Abstract

Inhaled corticosteroids are being given to more patients, at increasing doses and for longer periods of time. This has led to renewed concern about side-effects, particularly when higher doses (> 1 mg day-1) are used. The side-effects of particular concern are adrenocortical suppression, bone resorption, decreased growth in children, skin thinning and cataract formation. Changes in adrenocortical function are seen in a small proportion of patients given doses of 1-2 mg day-1. Long-term studies of the effect of inhaled corticosteroids on bone density are not available. Cross-sectional studies of bone density have been performed, but confounding variables, such as previous courses of oral corticosteroids and poor matching of control groups, make the studies difficult to interpret. Short-term effects on markers of bone turnover have been demonstrated, but their relevance to the long-term risk of osteoporosis is unclear. Studies reporting an increased incidence of skin changes and cataract formation are difficult to interpret because of confounding variables and inadequate control groups. Further studies of the long-term side-effects of inhaled corticosteroids are now required to enable prescribers to judge better the relative benefits and risks of this important asthma therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497712     DOI: 10.1016/s0954-6111(05)80254-9

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  2 in total

1.  Risk of adverse gastrointestinal events from inhaled corticosteroids.

Authors:  Richard A Hansen; Wanzhu Tu; Jane Wang; Roberta Ambuehl; Clement J McDonald; Michael D Murray
Journal:  Pharmacotherapy       Date:  2008-11       Impact factor: 4.705

Review 2.  Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review.

Authors:  Matthew J Dyer; David M G Halpin; Ken Stein
Journal:  BMC Fam Pract       Date:  2006-06-05       Impact factor: 2.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.